# Sotera Health Co.


**SHC**

Nasdaq; healthcare; SIC 8090, Services-Misc Health & Allied Services, NEC; CIK 0001822479

# C/D

**on the C/D boundary of 305 graded peers in healthcare**

rank 178 of 305; percentile 58.2; sampling error 2.8 points; lower is stronger





**C/D, the tortoise**



## Scoreboard


| | | |
|---|---|---|
| **Profitability** | B/C | percentile 40.9 |
| **Solvency** | D | percentile 65.1 |
| **Growth and financing** | C | percentile 43.3 |
| **Reliability** | 0.94 AUC | filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year | Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets | total assets $3.3B |
| **Standard universe** | inside | revenue above $1M and assets above $10M |
| **Warnings** | none triggered | not computable: distress |
| **Inputs computable** | 8 of 13 | |
| **Graded from** | filings received through Feb 24, 2026 | 269 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026 |
| **Last close** | $16.21 | 2026-11-19; market equity $4.6B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 24, 2026*

We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue).

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 40.9** | | | | | | |
| Gross profitability | 19.8% | 32.8% | | 64.6 | 346 | 2025-12-31 |
| Return on invested capital | not computable | 9.6% | | | | |


*latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Accruals ratio | (6.6%) | (6.7%) | | 55.5 | 756 | 2025-12-31 |
| Gross margin stability, five years | 0.4 pts | 2.8 pts | | 2.5 | 237 | 2025-12-31 |
| **Solvency, sleeve percentile 65.1** | | | | | | |
| Altman Z double-prime | not computable | 0.31 | | | | |
| *latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Interest coverage | not computable | (3.61x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 2.46x | 2.68x | | 65.1 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 43.3** | | | | | | |
| Revenue growth, three-year compound | 5.1% | 9.6% | | 60.2 | 400 | 2025-12-31 |
| Free cash flow growth, three-year compound | 16.0% | 11.1% | | 48.4 | 94 | 2025-12-31 |
| Reinvestment rate | not computable | 33.9% | | | | |
| *latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Asset growth, three years | 1.5% | 3.2% | | 48.8 | 663 | 2025-12-31 |
| Net share issuance, one year | 0.3% | 1.6% | | 16.0 | 625 | 2026-02-17 |

## Among 305 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 173 | Perrigo Co. plc (PRGO) | 56.6 | C | |
| 174 | Cryo Cell International Inc. (CCEL) | 56.9 | C | distress |
| 175 | Teladoc Health, Inc. (TDOC) | 57.2 | C | fortress balance sheet |
| 176 | Emergent BioSolutions Inc. (EBS) | 57.6 | C/D | |
| 177 | Abbott Laboratories (ABT) | 57.9 | C/D | |
| 178 | Sotera Health Co. (SHC) | 58.2 | C/D | |
| 179 | Medtronic plc (MDT) | 58.6 | C/D | |
| 180 | Neuronetics, Inc. (STIM) | 58.9 | C/D | |
| 181 | Cooper Companies, Inc. (COO) | 59.2 | C/D | |
| 182 | Aquestive Therapeutics, Inc. (AQST) | 59.5 | C/D | |
| 183 | AdaptHealth Corp. (AHCO) | 59.9 | C/D | |

## What the price implies

*at the 2026-11-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 11.4% | (1.7%) | 56 |
| Distance from 52-week high | (17.2%) | (31.7%) | 67 |
| EBIT to enterprise value | 4.7% | 0.5% | 75 |
| Free cash flow yield | 3.2% | 0.6% | 65 |
| Book value to price | 0.16 | 0.29 | 32 |
| Sales to price | 0.25 | 0.37 | 37 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Composite equity issuance, five years | not computable | 13.5% | |
| Relative strength against the sector, log excess return | (0.06) | (0.19) | 56 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 7 of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $412.4M |
| Operating cash flow, four quarters | $331.6M |
| Months of runway | not finite |
| Days since last periodic filing | 17 (10-Q received Nov 3, 2026) |
| Median daily dollar volume, 63 sessions | $36.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $645.5M | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 2 | assets | us-gaap:Assets | $3.3B | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $297.6M | 2024-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $113.9M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $69.5M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 6 | total debt | us-gaap:LongTermDebt | $2.2B | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 7 | book equity | us-gaap:StockholdersEquity | $404.9M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $277.2M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 9 | total debt | us-gaap:LongTermDebt | $2.2B | 2023-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 10 | book equity | us-gaap:StockholdersEquity | $443.7M | 2023-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $296.4M | 2023-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 12 | net income | us-gaap:NetIncomeLoss | $77.9M | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $287.2M | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 14 | assets | us-gaap:Assets | $3.1B | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.2B | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 16 | gross profit | us-gaap:GrossProfit | $602.3M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.1B | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 18 | gross profit | us-gaap:GrossProfit | $577.2M | 2023-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.0B | 2023-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 20 | gross profit | us-gaap:GrossProfit | $557.0M | 2022-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.0B | 2022-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 22 | gross profit | us-gaap:GrossProfit | $518.7M | 2021-12-31 | 2024-02-27 | 10-K | 24-000011 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $931.5M | 2021-12-31 | 2024-02-27 | 10-K | 24-000011 |
| 24 | current assets | us-gaap:AssetsCurrent | $526.0M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $191.0M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$610.0M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 27 | liabilities | us-gaap:Liabilities | $2.7B | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $84.3M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 29 | current assets | us-gaap:AssetsCurrent | $613.4M | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 30 | current liabilities | us-gaap:LiabilitiesCurrent | $249.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $138.0M | 2025-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $224.2M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $179.1M | 2024-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$147.7M | 2023-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $215.0M | 2023-12-31 | 2026-02-24 | 10-K | 26-000015 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $278.0M | 2022-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $182.4M | 2022-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 38 | current assets | us-gaap:AssetsCurrent | $557.2M | 2023-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 39 | current liabilities | us-gaap:LiabilitiesCurrent | $230.7M | 2023-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 40 | assets | us-gaap:Assets | $3.1B | 2023-12-31 | 2025-02-27 | 10-K | 25-000015 |
| 41 | assets | us-gaap:Assets | $3.1B | 2022-12-31 | 2024-02-27 | 10-K | 24-000011 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 284,392,079 | 2026-02-17 | 2026-02-24 | 10-K | 26-000015 |
| 43 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 283,473,342 | 2025-02-20 | 2025-02-27 | 10-K | 25-000015 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.